Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.4800 (1.92%) ($8.0500 - $8.5300) on Thu. Apr. 4, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.23% (three month average) | RSI | 75 | Latest Price | $8.4800(1.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.8% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) IWO(57%) ARKK(56%) | Factors Impacting TGTX price | TGTX will decline at least -2.615% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-7%) IFRA(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.615% (StdDev 5.23%) | Hourly BBV | 0 () | Intraday Trend | 1.8% | | | |
|
5 Day Moving Average | $8.24(2.91%) | 10 Day Moving Average | $7.74(9.56%) | 20 Day Moving Average | $7.4(14.59%) | To recent high | 0% | To recent low | 63.4% | Market Cap | $1.074b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |